We are excited to announce that Actelion Pharmaceuticals US, Inc. has awarded ACHA with two grants totaling $200,000 to support 2012 program activities.
The first $100,000 grant will support the Provider Action for Treating Congenital Hearts (PATCH) Program. As a new program area for ACHA, the PATCH Program will support a wide range of activities, including a needs analysis of adult congenital heart disease educational needs for medical professionals, an expansion of ACHA’s ACHD Online Program Directory, the development of new in-person and remote CME activities, print materials, professional networking opportunities, and other activities aimed to improve the availability and quality of national adult congenital heart disease care.
The second $100,000 grant will support the Heart to Heart Program, which helps patients take an active role in their cardiac care by providing a toolkit of resources with the information and skills they need to thrive with congenital heart disease, including web-based resources, educational events and peer support programs. This grant will help ACHA continue its great work, as well as allow the organization to extend the Heart to Heart Ambassadors program to offer localized peer-to-peer outreach, support, and information through targeted adult congenital heart disease programs.
“ACHA is incredibly thankful to Actelion for its continued support and commitment to our work with those in the congenital heart disease community,” says ACHA President/CEO Amy Verstappen. “With these grants, not only will ACHA be able to continue our important work with patients through the Heart to Heart Program, but we are also excited to dramatically increase our offerings and activities to ACHD providers through the PATCH Program.”